Skip to main contentSkip to navigation

Frog regrows amputated leg after drug treatment

Nearly complete limb develops over 18 months, raising exciting possibilities for human patients

African Clawed Frog
The African clawed frog’s leg start regrowing after just 24 hours of drug treatment. Photograph: Joe Blossom/Alamy
The African clawed frog’s leg start regrowing after just 24 hours of drug treatment. Photograph: Joe Blossom/Alamy

A frog has regrown a lost leg after being treated with a cocktail of drugs in a significant advance for regenerative medicine.

The African clawed frog, which is naturally unable to regenerate its limbs, was treated with the drugs for just 24 hours and this prompted an 18-month period of regrowth of a functional leg. The demonstration raises the prospect that in the future drugs could be used to switch on similar untapped abilities for regeneration in human patients to restore tissues or organs lost to disease or injury.

“It’s exciting to see that the drugs we selected were helping to create an almost complete limb,” said Nirosha Murugan of Tufts University in Massachusetts and first author of the paper. “The fact that it required only a brief exposure to the drugs to set in motion a months-long regeneration process suggests that frogs and perhaps other animals may have dormant regenerative capabilities that can be triggered into action.”

Many creatures are able to fully regenerate at least some limbs, including salamanders, starfish, crabs and lizards. Flatworms can even be chopped into pieces, with each piece reconstructing an entire organism.

Humans have some regenerative capabilities – the liver can regrow to full size after being halved and children can regrow the tips of their fingers. However, the loss of a large, complex limb cannot be restored by any natural process in mammals. The rapid formation of scar tissue protects us from blood loss and infection, but also prevents regrowth.

In the latest research, published in the journal Science Advances, the scientists amputated a frog’s hind-leg and enclosed the wound in silicone cap containing a five-drug cocktail. The drugs each had a different purpose, including reducing inflammation and the production of collagen to stop scar tissue growing. The drugs also aimed to promote the growth of new nerve fibres, blood vessels and muscle.

The experiment was repeated in dozens of frogs and many of those treated had a dramatic regrowth of tissue, with many re-creating an almost fully functional leg, including bone tissue and even toe-like structures at the end of the limb.

The regrown limb moved, responded to touch and the frogs were able to make use of it for swimming.

In the first few days of treatment scientists observed the activation of molecular pathways that are normally used to map out limbs in the developing embryo. They believe that adult humans still retain the information needed to make body structures and that, in theory, it should be possible to tap into this dormant ability.

“Covering the open wound with a liquid environment under the [silicone cap], with the right drug cocktail, could provide the necessary first signals to set the regenerative process in motion,” said Michael Levin, Vannevar Bush professor of biology and director of the Allen Discovery Center at Tufts. The team now plan to test the technique in mammals.

Bob Lanza, head of Astellas Global Regenerative Medicine, who was not involved in the research, described the advance as an “amazing achievement”.

“The study has extremely exciting ramifications for regenerative medicine,” said Lanza. “Although frogs have much greater regenerative capacity than humans, this is a very important first step. With the right combination of drugs and factors a similar approach could potentially spur regeneration and restore lost function in humans.”

Michael Schneider, a professor in cardiology at Imperial College London, said that the findings could have applications in other areas of regeneration, such as the possibility of scarless healing, after a heart attack. “The results are highly intriguing for human regenerative medicine, beyond just their implications for the limb,” he said. “As the authors acknowledge, a crucial step to be made before any human testing will be proof that this approach, possibly with further refinements, also can be applied to mammals.”

As 2022 begins, there’s a new year resolution we’d like you to consider. We’d like to invite you to join more than 1.5 million people in 180 countries who have taken the step to support us financially – keeping us open to all, and fiercely independent.

In 2021, this support sustained investigative work into offshore wealth, spyware, the 6 January insurrection, the corporate actors behind the climate crisis and the abuses of Big Tech. It enabled diligent, fact-checked, authoritative journalism to thrive in an era of falsehood, sensation, hype and breathtaking misinformation and misconception.

In 2022, we’ll be no less active, with the US midterms, the ongoing fight for racial justice, the next round in the struggle against the pandemic and a World Cup.

With no shareholders or billionaire owner, we can set our own agenda and provide trustworthy journalism that’s free from commercial and political influence, offering a counterweight to the spread of misinformation. When it’s never mattered more, we can investigate and challenge without fear or favour.

Unlike many others, Guardian journalism is available for everyone to read, regardless of what they can afford to pay. We do this because we believe in information equality. While others commoditise information, we seek to democratise it. Greater numbers of people can keep track of global events, understand their impact, and become inspired to take meaningful action.

If there were ever a time to join us, it is now. Every contribution, however big or small, powers our journalism and sustains our future. Support the Guardian from as little as $1 – it only takes a minute. Thank you.


Contribution frequency

Contribution amount
Accepted payment methods: Visa, Mastercard, American Express and PayPal